Floatz logo

azd6738

Prolymphocytic Leukaemia (PLL)

AstraZenecaPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

22 Active assets in the Prolymphocytic Leukaemia (PLL) cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Center for International Blood and Marrow Transplant Research
Phase 2BBB
Fludarabine
Center for International Blood and Marrow Transplant Research
Phase 3BB
FILGRASTIM
Center for International Blood and Marrow Transplant Research
Phase 2BB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 3BB
TACROLIMUS
Center for International Blood and Marrow Transplant Research
Phase 2BB

View all 50 →

Same molecule, other indications

azd6738 is also rated in:

small cell lung carcinomaDormant
B
Indicative ·
62 / 100
View asset →
squamous cell carcinomaDormant
B
Indicative ·
57 / 100
View asset →
adenocarcinomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →